Ask AI

Unlocking the Full Potential of HER2-Directed ADCs in HER2-Mutant and Overexpressing Lung Cancer: Testing Applications, Data Insights, and Effective Decision-making for Patient-Centric Care

Improve your understanding of HER2-directed ADCs for the management of your patients with HER2-mutant and HER2 overexpressing NSCLC based on the latest clinical data and guidelines to implement personalized treatment plans through microlearning video modules, a certified text module, expert-authored commentaries, and accompanying downloadable slides.

Share

Program Content

Activities

Targeting HER2 in NSCLC
HER2 in Context in NSCLC, Testing Strategies and Advances in Methodologies, and a Brief Review of ADCs in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2025

HER2 Directed ADCs in NSCLC
Data on HER2-Targeted Therapies in NSCLC, Practical Applications of HER2-Targeted Therapy, and Management of Treatment-Emergent Adverse Events
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2025

Activities

HER2 Directed ADCs in NSCLC
Evolving Role of HER2-Directed Antibody–Drug Conjugates in the Management of Patients With Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 05, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.